Skip to main content

Weather Alert

Hurricane Helene is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide
Quest Diagnostics

AMPAR2 Encephalopathy: A Recently Described Reversible Cause of Cognitive Impairment

AMLI 2021: 34th Annual Scientific Meeting (The Association of medical Laboratory Immunologists)
Austin, TX, August 13-16, 2021

AMPAR2 Encephalopathy: A Recently Described Reversible Cause of Cognitive Impairment

Authors: Luo A, Saadatpour L, Tanwir A, Naides SJ, Parker AS

Specialties: Neurology, Immunology

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.